Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss the rationale for investigating triplet therapies in acute myeloid leukemia.
Back
Exploring Triplet Therapies in Frontline Acute Myeloid Leukemia Management
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, explore research behind triplet therapies in acute myeloid leukemia.
Exploring Triplet Therapies in Frontline Acute Myeloid Leukemia Management
Episodes
All
All
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss data from MD Anderson Cancer Center on triplet therapies in AML with IDH mutations.
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, detail populations in AML that could derive benefit from triplet therapies.
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss data for venetoclax plus azacitidine vs induction chemotherapy in newly diagnosed, fit AML.
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential triplet strategies with menin inhibitors for KMT2A-rearranged AML.
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential treatment strategies in AML following triplet therapy and transplant.
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential dose modification approaches for the use of triplet therapy in AML.
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, highlight other key AML data from the 2025 ASH Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
3
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
4
European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer
5